GLP-1 dosing is personalized, and patients should follow their prescription label and provider instructions. Patients should not change their dose, injection frequency, medication type, or restart treatment on their own.
If a patient has missed doses, stopped treatment, or wants to increase or decrease their dosage, or is switching between semaglutide and tirzepatide, they should contact their prescriber through Medical Chat.
Why GLP-1 doses are increased gradually
GLP-1 medications are often started at a lower dose and increased gradually. This process is called titration.
Starter doses are intentionally low to allow the body to adjust and minimize side effects, which is a normal part of the process and does not indicate that the medication is ineffective.
Gradual titration may help:
Reduce nausea and gastrointestinal side effects.
Give the body time to adjust.
Help the patient and prescriber identify an effective dose.
Support safer long-term treatment. During the early stages of treatment, it is common to still feel hunger and cravings as the medication’s appetite-suppressing effects may not be noticeable right away. A new block could be added here to specifically address hunger management during titration, providing practical tips and reassurance.
Patients should not move up faster than instructed.
Patients should adhere to a strict 7-day interval between injections and should not take extra doses even if they feel hungry.
Semaglutide dosing and titration
GobyMeds semaglutide treatment uses a gradual dose schedule. The exact schedule depends on the patient’s prescription, assigned plan, medication supply, and provider guidance.
Patients should follow the instructions provided with their medication. If the dose shown in the portal differs from the label on the medication package, the patient should contact GobyMeds before injecting.
Tirzepatide dosing and titration
GobyMeds tirzepatide treatment also uses a gradual titration schedule. The exact schedule depends on the patient’s prescription, assigned plan, medication supply, and provider guidance.
Patients should follow the instructions provided with their medication. If the dose shown in the portal differs from the label on the medication package, the patient should contact GobyMeds before injecting.
Unit conversions between semaglutide and tirzepatide
Tirzepatide and semaglutide are not directly interchangeable milligram-for-milligram.
Patients should not compare their tirzepatide dose to someone else’s semaglutide dose, and they should not convert between medications without provider guidance.
Some GLP-1 prescriptions may include dose instructions using milligrams or milliliters, but most will explicitly specify the number of syringe units required per dosage. The unit amount may vary from vial to vial depending on the concentration of the medication, which is printed on the vial label. Patient’s must always follow their prescribed number of unit.
General conversion concepts:
Syringe units measure volume.
Milliliters measure liquid volume.
Milligrams measure medication amount.
Concentration determines how many milligrams are in each milliliter.
A common U-100 insulin syringe uses this volume convention:
1 unit = 0.01 mL
10 units = 0.10 mL
50 units = 0.50 mL
100 units = 1.00 mL
Patients should not calculate their own dose if they are unsure. They should contact GobyMeds if the label, syringe units, or portal instructions are confusing.
Starter and step-up plans
Starter and step-up plans are designed to help patients increase gradually over time. Starter bundles typically follow a structured 12-week dosing plan, starting at the lowest dose and progressively increasing to allow the body to acclimate and reach a therapeutic level. For example, tirzepatide doses may progress from 1.5 mg to 9 mg, and semaglutide doses may start at 0.2 mg and increase to 1.5 mg by week 12. These examples may vary based on individual prescriptions and pharmacy practices.
A starter plan may be appropriate for:
New GLP-1 patients.
Patients restarting after a significant break.
Patients who need a slower dose increase for tolerability.
Patients who prefer a structured plan to safely reach an effective dosage.
Patients who may benefit from a gradual approach to minimize side effects.
A step-up plan may be appropriate for:
Patients who are ready to increase their dosage.
Patients whose prescriber recommends a gradual increase. Step-up plans gradually increase doses to help the body adjust, while static-dose plans maintain the same dose throughout the treatment period, typically for patients who already know their optimal dose.
Patients should use the plan assigned to them and should not skip ahead. Starter bundles may also consolidate medication into fewer vials based on the total required for the titration plan. Clear dosing instructions are provided to ensure patients can safely increase their dose using the same vial when appropriate, streamlining the treatment process.
Restarting after missed doses or a treatment break
Patients should not restart at a high previous dose after a significant lapse. The longer the break, the more likely it is that the prescriber will recommend restarting at a lower dose and titrate back up.
If a patient has been off medication, they should contact Customer Support for a provider-directed restart plan before injecting again.
Twice-weekly dosing adjustments
GobyMeds does not explicitly offer a standard twice-weekly dosing regimen as a default plan. In some cases, a twice-weekly schedule may be available as an adjustment to an existing prescription if the prescriber determines it is appropriate.
Patients interested in splitting a weekly dose into twice-weekly injections should contact their prescriber through Medical Chat. This option may require purchasing extra syringes locally if additional syringes are needed.
Patients should not split doses or change injection frequency without prescriber approval.
If medication does not feel effective
If medication does not feel effective, patients should not increase their dose on their own.
Patients should:
Confirm they are following the label and injection schedule.
Remember that response can vary by person and by dose phase.
Stay consistent with nutrition, hydration, and movement habits.
Contact Medical Chat if they want to adjust dose, switch medication, or discuss effectiveness.
Many patients begin to notice reduced cravings, less frequent hunger, and longer-lasting fullness after 2–3 months or when reaching higher doses.